Screening critical genes associated with malignant glioma using bioinformatics analysis

Area of Science:

• Neuroscience
• Genomics
• Oncology

Background:

• Malignant gliomas are aggressive brain tumors with complex molecular underpinnings.
• Understanding gene expression differences across glioma grades is crucial for identifying therapeutic targets.

Purpose of the Study:

• To identify differentially expressed genes (DEGs) and key molecular players in the progression of malignant gliomas.
• To analyze gene expression profiles from astrocytomas of varying grades (II, III, and IV).

Main Methods:

• Downloaded and analyzed gene expression data (GSE54004) for astrocytomas.
• Utilized R's Limma package for DEG analysis between glioma grades.
• Performed Venn diagram, enrichment, and protein-protein interaction (PPI) network analyses.
• Identified glioma-associated and marker genes using the CTD database.

Main Results:

• Identified 27, 1,446, and 776 DEGs in grade III vs. II, grade IV vs. II, and grade IV vs. III astrocytomas, respectively.
• Matrix metalloproteinase 9 (MMP9) and chitinase 3-like 1 (CHI3L1) were significantly enriched.
• Annexin A1 (ANXA1) showed a high degree in PPI networks, and MMP9 interacted with vascular endothelial growth factor A (VEGFA).
• Ten common glioma marker genes, including MMP9, CHI3L1, VEGFA, and S100 calcium binding protein A4 (S100A4), were identified between grade IV vs. II and grade IV vs. III comparisons.

Conclusions:

• Malignant glioma progression involves significant alterations in gene expression.
• MMP9, CHI3L1, VEGFA, S100A4, and ANXA1 are potential key players in glioma development and progression.
• These identified genes represent potential biomarkers and therapeutic targets for high-grade gliomas.